ArticleScientific reports2025
Reduced ZMPSTE24 expression leads to prelamin accumulation and development of steatosis in MASLD patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Underexplored Mechanobiology of Lamin A Biogenesis and Homeostasis.Biology of the cell · 2026Review
- Review
- Prelamin A accumulation overlaps increased vascular calcification in peripheral artery disease and regulates vascular smooth muscle cells mineralization in diabetes mellitus.Atherosclerosis plus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Metabolic-associated steatotic liver disease (MASLD) is highly prevalent in type 2 diabetes mellitus (T2D) and its incidence has increased with the obesity epidemic. Mutations of nuclear lamina-associated genes including LMNA have been associated with fatty liver. We previously described a mechanism relating changes at the nuclear lamina that lead to opening of previously repressed chromatin and upregulation of lipid synthesis and storage pathways to development of steatosis in MASLD. Here we report that the changes at the nuclear envelope in MASLD patients are caused by downregulation of zinc metalloproteinase Ste24 (ZMPSTE24), an enzyme that processes prelamin to mature lamin A, leading to accumulation of prelamin. In addition, Zmpste24 mutant mice develop hepatic steatosis and exhibit upregulation of p53 target genes. Functional analysis determined p53 as a regulator in genes differentially expressed and bound by FOXA2 in MASLD patients, corresponding to observations in Zmpste24 knockout animals. ZMPSTE24 expression is repressed by mir-141-3p in male MASLD patients. Downregulation of ZMPSTE24 leads to the nuclear lamina changes responsible to development of MASLD we had previously reported. Hence, MASLD should be considered as a type of laminopathy and approaches to restore ZMPSTE24 expression and nuclear lamina function should be tested for treatment of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.